Among patients with obstructive sleep apnea using CPAP, pitolisant given at 20 mg and 40 mg reduces excessive daytime sleepiness.

Among patients with obstructive sleep apnea and excessive daytime sleepiness-related cognitive impairment, 2-week solriamfetol led to cognitive function improvement on three tests/scales, according to ...

People with certain types of long-term sleep disorders feel extremely tired during the day, a condition known as excessive daytime sleepiness (EDS). There are many medicines that work in different ...

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...

If you have a long-term sleep disorder that causes excessive daytime sleepiness (EDS), you may need to take medicines to manage your symptoms. The different medicines available for these ...

Women aged 80 and older who experience increased sleepiness are twice as likely to develop dementia as those with stable ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Given sleep’s profound impact on well-being, unexplained daytime fatigue and disrupted sleep patterns necessitate a ...

UC San Francisco study finds women over 80 who experience increased daytime sleepiness face twice the risk of developing dementia.

Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial ...

with and without severe excessive daytime sleepiness (EDS). In the overall patient population, the study did not demonstrate a statistically significant change on the Montgomery-Åsberg Depression ...